Gilead and Galapagos announce global collaboration to address inflammatory diseases. 2017. GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. In 2019, we further solidified our commitment, entering into a 10-year global research and development collaboration. UNBP5787 10/20, For news on Gilead and Galapagos’ continuing innovation in UC. In 2015, Gilead entered into a global partnership with Belgium-based biotech Galapagos. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, … GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV. Gilead and Galapagos partnered to develop filgotinib as treatment for rheumatoid arthritis. 2015. Gilead will pay $3.95 billion up front and make a further $1.1 billion equity investment in a new deal with Belgian biotech Galapagos. Galapagos NV and Gilead Sciences Inc. are stopping late-stage clinical trials of an experimental treatment for a progressive lung disease following a … Galapagos runs these programs until candidate drug, Phase 1 or Phase 2, ... Gilead. In 2015, Gilead and Galapagos formed a global partnership. Bitcoin Whipsaws Investors With Same-Day Plunge, Rally of 30%, Crypto Tumble Wipes $600 Billion Off Digital Tokens in a Week, U.S. Stocks Mixed; Yields Rise on Fed Minutes: Markets Wrap, Apple Readies MacBook Pro, MacBook Air Revamps, The World Economy Is Suddenly Running Low on Everything. In 2019, we further solidified our commitment, entering into a 10-year global research and development collaboration. Our stories . FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Feb. 10, 2021-- Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The newly inked agreement dwarfs the prior version financially, with Galapagos receiving $3.95bn (€3.5bn) upfront and $1.1bn in equity investment. Gilead will acquire the shares at 58 euros apiece, or 10 percent above the stock’s closing price on Wednesday. Galapagos’ colossal deal with Gilead is only one of many examples of this. Gilead will acquire about 15 percent of Galapagos for $425 million and pay a license fee of $300 million as part of an agreement to develop and sell filgotinib, a treatment for rheumatoid arthritis and other inflammatory diseases, according to a statement on Thursday. Galapagos and Gilead Soldier On After Inflammatory Disease Flops Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. As part of the transaction, Gilead made a $1.1B equity investment, increasing Gilead’s stake in Galapagos from approximately 12.3% to 22% of the issued and outstanding shares in Galapagos. In 2019, we further solidified our commitment, entering into a 10-year global research and development collaboration. Have a confidential tip for our reporters? 2016. Galapagos had lost more than a third of its value in the days following that surprise announcement. Gilead initiates Phase 3 studies of a Janus kinase 1 (JAK1) inhibitor for patients with rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Gilead is paying a 10% premium to Friday’s closing price for the increased stake in Galapagos, but has a 10-year standstill agreement preventing it from … Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead. The move would also accelerate Gilead’s entry into rheumatoid arthritis, where it has two compounds in the first phase of clinical development, according to the company’s website. Galapagos’s drug is about to enter the third and final stage, and works differently than Gilead’s molecules. Shares of Galapagos jumped to a record in Amsterdam trading. In 2015, Gilead and Galapagos formed a global partnership. Gilead and Galapagos initially linked up through a 2015 deal centered around filgotinib. The trial completed in Feb 2015 and the results were released in July 2015. The FDA is only one of the regulators reviewing filgotinib. The decision is based on the … Galapagos has had an alliance in inflammatory and autoimmune treatment with Gilead since 2015. In 2015, Gilead and Galapagos formed a global partnership. Gilead Sciences, Inc. GILD and partner Galapagos NV GLPG announced that the European Commission (EC) has granted marketing authorization to rheumatoid arthritis (RA) drug, Jyseleca (filgotinib 200 mg and 100 mg tablets). All stories Galapagos announced that the drug met key efficacy endpoints, showed ACR70 responses up to 39%, and maintained its safety profile. Inflammatory diseases Galapagos and Gilead have been collaborating since 2015 on the development and, later the commercialization, of filgotinib in inflammatory diseases. Others include the €1B acquisition of US firm Promedior by Roche in February — which centers on treatments for idiopathic pulmonary fibrosis — and an ongoing big pharma appetite for biotechs developing drugs against an inflammatory disease target called NLRP3. This was just the beginning. As part of the transaction, Gilead made a $1.1B equity investment, increasing Gilead’s stake in Galapagos from approximately 12.3% to 22% of the issued and outstanding shares in Galapagos. It's what attracted Gilead when the companies began working together in 2015 — a partnership that since sprouted into a $5 billion research deal.It's also key to validating Galapagos' drugmaking capabilities. All rights reserved. — With assistance by Kristen Hallam, and Anjali Cordeiro, Galapagos eligible for $1.35 billion in additional payments, Shares of Galapagos surged in Amsterdam to record high. Gilead Sciences Inc. plans to pay $725 million to acquire a stake in Belgian drugmaker Galapagos NV and buy into an experimental drug that had been spurned by AbbVie Inc. less than three months ago. Before it's here, it's on the Bloomberg Terminal. Gilead Sciences Inc. plans to pay $725 million to acquire a stake in Belgian drugmaker Galapagos NV and buy into an experimental drug that had been spurned by AbbVie Inc. less than three months ago. In 2015, Gilead Sciences gave Galapagos $725 million upfront to co-develop filgotinib. 3 Using Galapagos’ unique platform, we’re utilizing disease-related, human primary cell–based assays to discover and verify novel drug targets. Galapagos’ alliance strategy combines novel targets and candidate drugs discovered by Galapagos with patient expertise from Galapagos’ pharma partners. Galapagos is also eligible to get an additional $1.35 billion in payments for meeting certain milestones in developing the drug. © 2020 Gilead Sciences, Inc. With Gilead’s history of dismantling diseases and the unique Galapagos drug discovery platform, we believe we can make an impact on inflammation and improve the lives of patients living with UC. However, in 2015, Galapagos sold the rights to filgotinib to Gilead for a 15% (25% now in 2019), $425mn stake in Galapagos, $1.35bn in milestone payments and between 20% and 30% in royalties. 2015. Galapagos will use the proceeds to expand and … Gilead and Galapagos also have a collaboration for the development and commercialization of filgotinib, originally signed in 2015, with a new agreement announced in December 2020. Gilead and Galapagos recently paused clinical trials of filgotinib in psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-infectious uveitis following receipt of the CRL and, without a viable path forward in the United States, the companies no longer believe it is feasible to continue the current global development program for filgotinib in these indications. Partnering with the Belgian biotech, which has largely focused on treatments for inflammation and fibrosis, offered Gilead a foothold in immunology at a time when the company was trying to diversify beyond its core business of infectious disease drugs. Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The transaction marks a comeback for the drug and its maker, which took a beating in September when AbbVie decided to drop its partnership with Galapagos to develop the treatment and instead move ahead with its own experimental rheumatoid arthritis pill. Its last big deal was the about $11 billion purchase of Pharmassett Inc. in 2012. 2 The partnership was further solidified in 2019 with a 10-year global research and development collaboration. Updates with Gilead pipeline in fifth paragraph. The two companies have been partners since 2015, with Gilead agreeing to pay $5.1 billion to raise its stake in the Belgian company in 2019 to gain rights to drugs in development. Galapagos surged 11 percent to 58.47 euros as of 10:31 a.m., after earlier touching an all-time high of 60.55 euros. DARWIN 2 trial Investors are waiting to see Gilead’s next move after the pharmaceutical company’s two hepatitis C treatments became the fastest-selling drugs of all time, with a combined $18.1 billion in sales in the last 12 months. Dive Insight: Filgotinib has become a defining drug for Galapagos. Galapagos suffered another disappointment in December when Gilead dropped its pursuit of U.S. approval for Jyseleca as a treatment for rheumatoid arthritis. Previously, Gilead had signed a potential multi-billion agreement with Galapagos in 2015, and the pair returned to the table to negotiate a 10-year extension to the deal.. The Foster City, California-based company has $15.7 billion in cash, equivalents and short-term investments on its books, and investors are waiting to see whether it makes a large acquisition.